Harrow, Inc. (NASDAQ:HROW) is Diametric Capital LP's 2nd Largest Position

Diametric Capital LP raised its position in Harrow, Inc. (NASDAQ:HROW - Free Report) by 49.0% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 110,295 shares of the company's stock after buying an additional 36,269 shares during the period. Harrow comprises 2.5% of Diametric Capital LP's investment portfolio, making the stock its 2nd biggest position. Diametric Capital LP owned approximately 0.31% of Harrow worth $3,700,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Quest Partners LLC acquired a new position in shares of Harrow during the 3rd quarter worth approximately $29,000. AlphaQuest LLC increased its holdings in Harrow by 452.8% in the 4th quarter. AlphaQuest LLC now owns 3,527 shares of the company's stock worth $118,000 after acquiring an additional 2,889 shares in the last quarter. Maridea Wealth Management LLC acquired a new position in Harrow during the fourth quarter worth $222,000. KLP Kapitalforvaltning AS purchased a new position in Harrow during the fourth quarter valued at $235,000. Finally, China Universal Asset Management Co. Ltd. grew its position in shares of Harrow by 10.7% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 7,552 shares of the company's stock valued at $253,000 after purchasing an additional 727 shares during the period. Hedge funds and other institutional investors own 72.76% of the company's stock.

Harrow Price Performance

NASDAQ HROW traded down $0.54 during trading hours on Friday, hitting $23.52. 520,963 shares of the company's stock traded hands, compared to its average volume of 504,940. The company has a market capitalization of $838.58 million, a PE ratio of -25.02 and a beta of 0.46. The company has a debt-to-equity ratio of 3.23, a current ratio of 1.55 and a quick ratio of 1.44. Harrow, Inc. has a 52-week low of $9.86 and a 52-week high of $59.23. The firm's 50-day moving average is $27.98 and its 200-day moving average is $37.36.

Harrow (NASDAQ:HROW - Get Free Report) last posted its quarterly earnings results on Thursday, March 27th. The company reported $0.25 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.11 by $0.14. Harrow had a negative return on equity of 45.57% and a negative net margin of 19.75%. The business had revenue of $66.83 million during the quarter, compared to analyst estimates of $66.01 million. Equities analysts forecast that Harrow, Inc. will post -0.53 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on HROW. B. Riley reduced their price target on shares of Harrow from $69.00 to $65.00 and set a "buy" rating for the company in a research report on Tuesday. HC Wainwright restated a "buy" rating and issued a $57.00 target price on shares of Harrow in a research report on Monday, March 31st.

Harrow Company Profile

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.